Evidence map›Paper›PMID 41811655›Full record

ArticleOncology and therapy2026

Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).

Cristina Papayannidis, Irina Amitai, Pascal Turlure, Ann De Becker, Felix Mensah, Dina Elsouda, Ioanna Vardounioti, Jose Alejandro Palacios-Fabrega, Paresh Vyas, Blanca Boluda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cristina PapayannidisIRCCS Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Irina AmitaiSheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Pascal TurlureLimoges University Hospital, Limoges, France.
Ann De BeckerUniversitair Ziekenhuis Brussel, Vrije Universiteit, Brussels, Belgium.
Felix MensahIndiana Blood and Marrow Transplant, Indianapolis, IN, USA.
Dina ElsoudaAstellas Pharma Inc., Northbrook, IL, USA.
Ioanna VardouniotiAstellas Pharma Europe Ltd., Addlestone, UK.ORCID http://orcid.org/0009-0001-4422-6066
Jose Alejandro Palacios-FabregaAstellas Pharma Europe Ltd., Addlestone, UK.ORCID http://orcid.org/0000-0001-7417-3391
Paresh VyasUniversity of Oxford, Oxford, UK. paresh.vyas@imm.ox.ac.uk.ORCID http://orcid.org/0000-0003-3931-0914
Blanca BoludaHematology Department, La Fe University Hospital, Valencia, Spain.ORCID http://orcid.org/0000-0002-1785-5561

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFMS-like tyrosine kinase 3 (FLT3) mutations show variable detectability in relapse/refractory acute myeloid leukemia (AML) with unclear clonal evolution dynamics.

methodsThis prospective noninterventional study examined clonal evolution and outcomes from AML diagnosis to relapse/refractory disease occurrences.

resultsOf 650 patients included, 172 were FLT3-positive (FLT3

conclusionsDynamic changes in FLT3 mutation status were observed during these patients' disease course. FLT3

Indexed as

AMLClonal evolutionFLT3 mutationsMutation detectionRelapsed/refractory diseaseTyrosine kinases

Identifiers

PMID41811655
PMCPMC13304035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.